Breakthrough Device Designation was granted to a urine-based VOC spectroscopy/ML MCED test targeting prostate, bladder, and kidney cancers, potentially broadening non-blood screening modalities.
Metformin consistently increased circulating Lac-Phe irrespective of disease stage, PSA response, or other tumor activity markers, indicating a metabolic signal uncoupled from antitumor efficacy in ...
Melissa Kestler, DNP, FNP-BC | Authors | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results